Nama's AI scorecard currently rates PACS Group Sell (3.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

What is PACS's P/E ratio?

PACS Group trades at a trailing price-to-earnings ratio of 20.1.

When does PACS report earnings?

PACS Group's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.65.

What is the PACS price target?

The median analyst price target from 6 analysts is $59.00, with a range of $57.00 – $62.00.

Is PACS Shariah compliant?

Nama's AAOIFI-style screen reads PACS Group as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

PACS Group (PACS)

Healthcare · Medical Care Facilities · NYSE

PACS Group (PACS) is a Healthcare company in the Medical Care Facilities industry. It has a market capitalization of $7.87B, a trailing price-to-earnings ratio of 20.1 and a free-cash-flow yield of 2.0%. Over the most recent reported fiscal year, revenue grew 29.3% and free cash flow per share grew 738.6%. Nama's AI scorecard rates it Sell, 3.3 out of 10. On 12-month momentum it ranks in the leading band of its market.

AI scorecard

Sell · 3.3/10

Negative, at the mild end of Sell. As of Nov 7, 2026.

Momentum

Leading · +246.1% over 12 months ex. last

Top 20% of its market on the past year's steady rise.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-4.0%

How far the last close sits under the highest price of the past five years.

Market cap	$7.87B
Trailing P/E	20.1
Price / book	7.1
Price / sales	1.4
FCF yield	2.0%
Dividend yield	—
Gross margin	16.6%
Operating margin	7.4%
Net margin	4.8%
Revenue growth (YoY)	+29.3%
Revenue growth (3-yr annual)	+29.7%
EPS growth (YoY)	—
FCF/share growth (YoY)	+738.6%
Beta	-0.1
Exchange	NYSE
Sector	Healthcare
Industry	Medical Care Facilities

PACS earnings

Next report: Feb 25, 2027 (Q4 2026, EPS estimate $0.65). Beat the EPS estimate in 4 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q3 2026	Nov 3, 2026	$0.63	$0.58	+8.6%	$1.50B
Q2 2026	Aug 4, 2026	$0.63	$0.56	+12.5%	$1.43B
Q1 2026	May 11, 2026	$0.64	$0.41	+56.1%	$1.42B
Q4 2025	Feb 26, 2026	$0.57	$0.46	+23.9%	$1.36B

PACS analyst price target

Median target $59.00 from 6 analysts, ranging $57.00 – $62.00.

Medical Care Facilities peers

Ticker	Company	Market cap	P/E
HCA	HCA Healthcare	$103.40B	16.5
THC	Tenet Healthcare	$22.55B	12.7
EHC	Encompass Health	$13.50B	22.4
FMS	Fresenius Medical Care	$12.15B	10.2
DVA	DaVita	$12.04B	13.6
UHS	Universal Health Services	$11.52B	8.6
ENSG	Ensign Group	$10.56B	23.8
CHE	Chemed	$6.84B	21.2

Explore live PACS data on Nama Insights →

PACS FAQ

Is PACS a buy?: Nama's AI scorecard currently rates PACS Group Sell (3.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
What is PACS's P/E ratio?: PACS Group trades at a trailing price-to-earnings ratio of 20.1.
When does PACS report earnings?: PACS Group's next scheduled report is on Feb 25, 2027. Analysts expect EPS of $0.65.
What is the PACS price target?: The median analyst price target from 6 analysts is $59.00, with a range of $57.00 – $62.00.
Is PACS Shariah compliant?: Nama's AAOIFI-style screen reads PACS Group as Not Shariah Compliant. At least one of the three ratios or the industry test failed.